Inovio got quick approval from the FDA for VOCERYQ, a treatment for a throat condition.

Oct 31, 2026, 9:42 AM ETTrialRead the original at morningstar.com

Good for INO

FDA approval gives Inovio a route to sell a treatment meant to reduce surgery for adults with RRP. The required follow-up study is a condition, but it does not outweigh the approval and planned launch.

INO · Inovio Pharmaceuticals

AI read · Good for INO

The AI's read

This gives Inovio a chance to sell a treatment intended to reduce surgery for adults with RRP. It is also the first U.S. approval for a plasmid DNA immunotherapy, supporting the company's delivery platform. Orders are expected in about 60 days, with a wider launch planned for early 2027. The required follow-up study leaves a condition to meet, but the approval and sales path make this positive.

Get alerts for INO

Follow Inovio Pharmaceuticals (INO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for INO

Free on the App Store and Google Play, or on the web.